A randomized study of alglucosidase alfa in late-onset Pompe's disease

Ans T. Van Der Ploeg, Paula R. Clemens, Deyanira Corzo, Diana M. Escolar, Julaine Florence, Geert Jan Groeneveld, Serge Herson, Priya S. Kishnani, Pascal Laforet, Stephen L. Lake, Dale J. Lange, Robert T. Leshner, Jill E. Mayhew, Claire Morgan, Kenkichi Nozaki, Dorothy J. Park, Alan Pestronk, Barry Rosenbloom, Alison Skrinar, Carine I. Van Capelle & 3 others Nadine A. Van Der Beek, Melissa P. Wasserstein, Sasa A. Zivkovic

Research output: Contribution to journalArticle

423 Citations (Scopus)

Abstract

BACKGROUND: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease. METHODS: Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC). RESULTS: At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1±13.1 m on the 6-minute walk test and an absolute increase of 3.4±1.2 percentage points in FVC; P = 0.03 and P = 0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8% of the patients). CONCLUSIONS: In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)

Original languageEnglish (US)
Pages (from-to)1396-1406
Number of pages11
JournalNew England Journal of Medicine
Volume362
Issue number15
DOIs
StatePublished - Apr 15 2010
Externally publishedYes

Fingerprint

Glycogen Storage Disease Type II
Vital Capacity
Placebos
Hyperhidrosis
Muscle Weakness
Urticaria
Anaphylaxis
Muscular Diseases
Glycogen
Walking
Vomiting
Ventilation
Thorax
Randomized Controlled Trials
Body Weight
Blood Pressure
Lung
Late Onset Disorders
human GAA protein
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Van Der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., ... Zivkovic, S. A. (2010). A randomized study of alglucosidase alfa in late-onset Pompe's disease. New England Journal of Medicine, 362(15), 1396-1406. https://doi.org/10.1056/NEJMoa0909859

A randomized study of alglucosidase alfa in late-onset Pompe's disease. / Van Der Ploeg, Ans T.; Clemens, Paula R.; Corzo, Deyanira; Escolar, Diana M.; Florence, Julaine; Groeneveld, Geert Jan; Herson, Serge; Kishnani, Priya S.; Laforet, Pascal; Lake, Stephen L.; Lange, Dale J.; Leshner, Robert T.; Mayhew, Jill E.; Morgan, Claire; Nozaki, Kenkichi; Park, Dorothy J.; Pestronk, Alan; Rosenbloom, Barry; Skrinar, Alison; Van Capelle, Carine I.; Van Der Beek, Nadine A.; Wasserstein, Melissa P.; Zivkovic, Sasa A.

In: New England Journal of Medicine, Vol. 362, No. 15, 15.04.2010, p. 1396-1406.

Research output: Contribution to journalArticle

Van Der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ, Herson, S, Kishnani, PS, Laforet, P, Lake, SL, Lange, DJ, Leshner, RT, Mayhew, JE, Morgan, C, Nozaki, K, Park, DJ, Pestronk, A, Rosenbloom, B, Skrinar, A, Van Capelle, CI, Van Der Beek, NA, Wasserstein, MP & Zivkovic, SA 2010, 'A randomized study of alglucosidase alfa in late-onset Pompe's disease', New England Journal of Medicine, vol. 362, no. 15, pp. 1396-1406. https://doi.org/10.1056/NEJMoa0909859
Van Der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. New England Journal of Medicine. 2010 Apr 15;362(15):1396-1406. https://doi.org/10.1056/NEJMoa0909859
Van Der Ploeg, Ans T. ; Clemens, Paula R. ; Corzo, Deyanira ; Escolar, Diana M. ; Florence, Julaine ; Groeneveld, Geert Jan ; Herson, Serge ; Kishnani, Priya S. ; Laforet, Pascal ; Lake, Stephen L. ; Lange, Dale J. ; Leshner, Robert T. ; Mayhew, Jill E. ; Morgan, Claire ; Nozaki, Kenkichi ; Park, Dorothy J. ; Pestronk, Alan ; Rosenbloom, Barry ; Skrinar, Alison ; Van Capelle, Carine I. ; Van Der Beek, Nadine A. ; Wasserstein, Melissa P. ; Zivkovic, Sasa A. / A randomized study of alglucosidase alfa in late-onset Pompe's disease. In: New England Journal of Medicine. 2010 ; Vol. 362, No. 15. pp. 1396-1406.
@article{57f7e1ecdc7f4bc3a8bf36bafbf3b65c,
title = "A randomized study of alglucosidase alfa in late-onset Pompe's disease",
abstract = "BACKGROUND: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease. METHODS: Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC). RESULTS: At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1±13.1 m on the 6-minute walk test and an absolute increase of 3.4±1.2 percentage points in FVC; P = 0.03 and P = 0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8{\%} of the patients). CONCLUSIONS: In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)",
author = "{Van Der Ploeg}, {Ans T.} and Clemens, {Paula R.} and Deyanira Corzo and Escolar, {Diana M.} and Julaine Florence and Groeneveld, {Geert Jan} and Serge Herson and Kishnani, {Priya S.} and Pascal Laforet and Lake, {Stephen L.} and Lange, {Dale J.} and Leshner, {Robert T.} and Mayhew, {Jill E.} and Claire Morgan and Kenkichi Nozaki and Park, {Dorothy J.} and Alan Pestronk and Barry Rosenbloom and Alison Skrinar and {Van Capelle}, {Carine I.} and {Van Der Beek}, {Nadine A.} and Wasserstein, {Melissa P.} and Zivkovic, {Sasa A.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1056/NEJMoa0909859",
language = "English (US)",
volume = "362",
pages = "1396--1406",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",

}

TY - JOUR

T1 - A randomized study of alglucosidase alfa in late-onset Pompe's disease

AU - Van Der Ploeg, Ans T.

AU - Clemens, Paula R.

AU - Corzo, Deyanira

AU - Escolar, Diana M.

AU - Florence, Julaine

AU - Groeneveld, Geert Jan

AU - Herson, Serge

AU - Kishnani, Priya S.

AU - Laforet, Pascal

AU - Lake, Stephen L.

AU - Lange, Dale J.

AU - Leshner, Robert T.

AU - Mayhew, Jill E.

AU - Morgan, Claire

AU - Nozaki, Kenkichi

AU - Park, Dorothy J.

AU - Pestronk, Alan

AU - Rosenbloom, Barry

AU - Skrinar, Alison

AU - Van Capelle, Carine I.

AU - Van Der Beek, Nadine A.

AU - Wasserstein, Melissa P.

AU - Zivkovic, Sasa A.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - BACKGROUND: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease. METHODS: Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC). RESULTS: At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1±13.1 m on the 6-minute walk test and an absolute increase of 3.4±1.2 percentage points in FVC; P = 0.03 and P = 0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8% of the patients). CONCLUSIONS: In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)

AB - BACKGROUND: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease. METHODS: Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC). RESULTS: At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1±13.1 m on the 6-minute walk test and an absolute increase of 3.4±1.2 percentage points in FVC; P = 0.03 and P = 0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8% of the patients). CONCLUSIONS: In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)

UR - http://www.scopus.com/inward/record.url?scp=77950963839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950963839&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0909859

DO - 10.1056/NEJMoa0909859

M3 - Article

VL - 362

SP - 1396

EP - 1406

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 15

ER -